In This Article:
As global markets exhibit mixed signals with the S&P 500 reaching new highs and sectors like technology leading the charge, investors are navigating through a landscape shaped by fluctuating interest rates and economic indicators. In such a market, growth companies with high insider ownership can be particularly compelling, as this combination often signals strong confidence in the company’s future from those who know it best.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 28.9% |
| Cettire (ASX:CTT) | 28.7% | 26.7% |
| Gaming Innovation Group (OB:GIG) | 26.7% | 36.9% |
| Credo Technology Group Holding (NasdaqGS:CRDO) | 14.7% | 60.9% |
| Plenti Group (ASX:PLT) | 12.8% | 106.4% |
| Vow (OB:VOW) | 31.8% | 97.6% |
| UTI (KOSDAQ:A179900) | 34.1% | 122.7% |
| Adocia (ENXTPA:ADOC) | 11.9% | 59.8% |
| EHang Holdings (NasdaqGM:EH) | 32.8% | 74.3% |
| HANA Micron (KOSDAQ:A067310) | 20% | 96.3% |
Let's dive into some prime choices out of from the screener.
Pharma Mar
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology use across various regions including Spain, Italy, Germany, Ireland, France, other parts of the European Union, and the United States with a market cap of approximately €0.67 billion.
Operations: The company generates €160.64 million from its oncology segment.
Insider Ownership: 11.8%
Revenue Growth Forecast: 17.8% p.a.
Pharma Mar, a company with significant insider ownership, is making strides in cancer treatment through its marine-derived drug Zepzelca® (lurbinectedin), particularly for Small Cell Lung Cancer. Recent Phase II trial results showcased promising response rates and manageable safety profiles, reinforcing its potential as a second-line treatment. Despite this innovation, revenue growth projections are modest at 17.8% annually, trailing behind the desired 20% mark but still outpacing the Spanish market's 4.7%. Earnings are expected to surge by 46.9% annually, significantly above Spain's average growth rate. However, profit margins have dipped from last year’s figures.
-
Click to explore a detailed breakdown of our findings in Pharma Mar's earnings growth report.
-
Upon reviewing our latest valuation report, Pharma Mar's share price might be too optimistic.
ShenZhen Woer Heat-Shrinkable MaterialLtd
Simply Wall St Growth Rating: ★★★★★★
Overview: ShenZhen Woer Heat-Shrinkable Material Co., Ltd. specializes in the production of heat-shrinkable materials, with a market capitalization of approximately CN¥20.27 billion.